

NEWS RELEASE

Onco-Innovations Announces Partnership with Dalton Pharma for Isotope Synthesis of Patented PNKP Technology

PNKP Technology Shown in Past Study to Increase Survival Rate in Colorectal Cancer Bearing Mice

Vancouver, Canada – April 17, 2025 – Onco-Innovations Limited (CSE: **ONCO**) (OTCQB: **ONNVF**) (Frankfurt: **W1H**, WKN: **A3EKSZ**) ("**Onco**" or the "**Company**") is pleased to announce that it has entered into an agreement with Dalton Pharma Services ("**Dalton**") dated April 8, 2025, for the custom synthesis of a heavy labelled isotope of its exclusively-licensed Polynucleotide Kinase 3'-Phosphatase (PNKP) inhibitor (the "**Technology**"), based on a nanoparticle formulation of second-generation PNKP inhibitor, which when used as a monotherapeutic, was shown to increase the survival time of PTEN-deficient colorectal cancer tumor-bearing mice in a June 2021 study¹ conducted by researchers at the University of Alberta ("**Study**"). This agreement with Dalton marks a critical step toward advancing IND-enabling animal model research, as the labelled compound will be used in upcoming ADME (Absorption, Distribution, Metabolism, and Excretion) studies.

The Study referenced above involved using a PTEN-deficient colorectal cancer (CRC) xenograft mouse model, intravenous administration of the nanoparticle-encapsulated A83B4C63 (the PNKP Inhibitor compound), which resulted in a noticeable increase in median survival. Mice treated with the A83B4C63 nano formulation showed a median survival time of 60 days, compared to 23 days in untreated controls, which highlights the therapeutic potential of A83B4C63 in PTEN-deficient CRC-bearing mice. Furthermore, the Technology was shown to enhance the effectiveness of PNKP inhibitors while reducing the impact on surrounding healthy tissues², making it a promising avenue for advancing cancer therapies. Increasing survival rates is a critical objective in cancer research, and the success of the Technology in this Study illustrates the potential benefits of targeted nanoparticle delivery systems.

"Not only did the Study show that the Technology reduces toxicity, precisely targets cancer cells, and prevents them from regrowing, but it has also been shown to increase the survival rate in colorectal cancer-bearing mice. This is a substantial piece of information that reaffirms why we are so optimistic about the formula. As such, we are taking further steps to move the Technology toward clinical trials," said Thomas O'Shaughnessy, CEO of Onco-Innovations.

Signing the contract with Dalton represents an important step in pursuing the next phase of studies required to support IND-enabling development, as the Company believes that, absent such work, Onco would be unable to generate the necessary data to advance the program effectively. The ADME studies in mice are a foundational component of Onco's IND-enabling strategy, aimed at de-risking the compound ahead of future regulatory submissions. By building on strong preclinical efficacy data and advancing toward regulatory readiness, the Company is making meaningful progress in the clinical translation of its PNKP Technology.

About Dalton Pharma Services

Dalton Pharma Services, established in 1986 and based in Toronto, Canada, is a Health Canada-approved and FDA-

¹ <https://doi.org/10.1016/j.jconrel.2021.04.034>

² <https://doi.org/10.1016/j.jconrel.2021.04.034>

inspected GMP contract provider of integrated chemistry, drug development, and manufacturing services to the pharmaceutical and biotechnology industries. With over 35 years of experience, Dalton offers a comprehensive range of in-house services, including drug discovery, flow chemistry, formulation and process development, custom synthesis, cGMP sterile fill/finish, cGMP API manufacturing, and dosage form manufacturing. This integration at a single location enhances adaptability, flexibility, and cost-effectiveness, accelerating drug discovery and development programs. Dalton's commitment to quality, speed, and flexibility has been recognized with CMO Leadership Awards from Life Science Leader in 2016, 2017, and 2018 across categories such as Quality, Reliability, Capabilities, Expertise, Compatibility, and Development.³

About Onco-Innovations Limited

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to prevent and cure cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours, setting new standards in cancer treatment. Onco's commitment to excellence and innovation drives it to develop advanced therapies that improve patient outcomes and offer hope in the fight against cancer.

ON BEHALF OF ONCO-INNOVATIONS LIMITED,

"Thomas O'Shaughnessy"

Chief Executive Officer

For more information, please contact:

Thomas O'Shaughnessy

Chief Executive Officer

Tel: + 1 888 261 8055

investors@oncoinnovations.com

The CSE and Information Service Provider have not reviewed and do not accept responsibility for the accuracy or adequacy of this release.

Forward-Looking Statements Caution. This news release contains forward-looking statements relating to the further development, potential commercialization and benefits of the Company's technologies, the Company's ability to submit and complete further clinical trials, the Company's ability to maintain reasonable commercial relations with contractual counterparties and the prospects of the Company, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to further develop, prove out or commercialize the Company's technologies, the failure to complete further clinical trials, the failure to maintain reasonable commercial relations with contractual counterparties, the failure to receive regulatory approval in respect of the Company's technologies, and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks,

³ <https://www.dalton.com/pharmaceutical-manufacturing>

uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.